The New England Journal of Medicine NOVEMBER 06, 2012

Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT)

Arthur J. Moss, et al.

Bottom Line

The MADIT-RIT trial demonstrated that high-rate or delayed-duration ICD programming significantly reduces the occurrence of inappropriate therapies and is associated with lower all-cause mortality compared to conventional programming in patients with a primary prevention indication.

Key Findings

1. High-rate therapy (≥200 bpm) significantly reduced the primary endpoint of first inappropriate therapy compared to conventional programming (4% vs. 20%; hazard ratio [HR] 0.21; 95% CI 0.13-0.34; p < 0.001).

2. Delayed-duration therapy (60-second delay at ≥170 bpm) also significantly reduced the first inappropriate therapy compared to conventional programming (5% vs. 20%; HR 0.24; 95% CI 0.15-0.40; p < 0.001).

3. High-rate therapy was associated with a statistically significant 55% reduction in the risk of all-cause mortality compared to conventional programming (HR 0.45; 95% CI 0.24-0.85; p = 0.01).

4. Delayed-duration therapy showed a trend toward reduced mortality (HR 0.56; 95% CI 0.3-1.02; p = 0.06), though this did not reach statistical significance.

Study Design

Design

RCT

Open-Label

Sample

1,500

Patients

Duration

1.4 yr

Median

Setting

Multicenter, 15 countries

Population Patients with a primary prevention indication for an ICD or CRT-D device.

Intervention Either high-rate therapy (VT zone ≥200 bpm) or delayed-duration therapy (60-second delay for VT zone ≥170 bpm).

Comparator Conventional programming (VT zone ≥170 bpm, 2.5-second delay).

Outcome First occurrence of inappropriate ICD therapy (antitachycardia pacing or shock).

Study Limitations

• The trial was sponsored by a device manufacturer (Boston Scientific) and utilized only their devices.

• The open-label nature of the trial could potentially introduce bias, although the primary endpoint was objective device-recorded data.

• The study focused exclusively on primary prevention patients, limiting the generalizability of the findings to secondary prevention populations.

• The mortality reduction, while clinically striking, was a secondary endpoint and warrants cautious interpretation given the open-label design.

Clinical Significance

The MADIT-RIT trial fundamentally changed clinical practice by establishing that aggressive, high-rate, or delayed detection programming in ICDs is superior to traditional, more sensitive settings. This approach reduces unnecessary device interventions (such as painful shocks and antitachycardia pacing) and improves patient survival, effectively shifting the standard of care for primary prevention ICD programming.

Historical Context

Prior to MADIT-RIT, ICDs were commonly programmed with conservative detection zones (e.g., ≥170 bpm) and short delays, resulting in a high burden of inappropriate therapies due to supraventricular tachycardias. This trial provided robust, large-scale randomized evidence that more conservative device detection thresholds are safe and clinically beneficial, addressing a major limitation of earlier device management strategies.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

What are the common physiological triggers that cause an ICD to deliver an 'inappropriate' shock, and why is the reduction of these events a primary goal in device management?

Key Response

Inappropriate shocks are typically triggered by supraventricular tachycardias (SVT), such as atrial fibrillation with rapid ventricular response, or by oversensing (e.g., T-wave oversensing or lead fracture). These events are problematic because shocks cause physical pain, psychological trauma (PTSD), and direct myocardial injury, which can paradoxically worsen heart failure or trigger further arrhythmias.

Resident

In a patient receiving an ICD for primary prevention, how would you program the zones and delays based on the MADIT-RIT protocol to optimize survival and reduce morbidity?

Key Response

Following MADIT-RIT, clinicians should avoid 'conventional' programming (e.g., detection at rates >170 bpm with short delays). Instead, they should utilize either a 'high-rate' strategy (detection only for rates ≥200 bpm) or a 'delayed-duration' strategy (detection for rates ≥170 bpm but with a 60-second delay before therapy), as both were shown to significantly reduce inappropriate shocks and all-cause mortality.

Fellow

The MADIT-RIT trial demonstrated a mortality benefit for both high-rate and delayed-duration arms. Compare the physiological implications of these two programming strategies regarding the 'natural history' of ventricular tachyarrhythmias.

Key Response

The high-rate arm (Arm B) essentially ignores slower VTs, while the delayed-duration arm (Arm C) allows time for VTs to self-terminate. The success of Arm C indicates that many VTs in primary prevention patients are non-sustained and hemodynamically tolerated; treating them immediately is not only unnecessary but harmful, suggesting that even 'appropriate' shocks for self-terminating VT can contribute to mortality.

Attending

MADIT-RIT is often cited for its impact on mortality. How do you explain to a trainee the mechanism by which reducing 'inappropriate' therapies translates into a significant reduction in 'all-cause' mortality?

Key Response

The mortality benefit likely stems from avoiding the deleterious effects of high-voltage shocks and unnecessary anti-tachycardia pacing (ATP). Shocks cause myocardial necrosis (elevated troponins), inflammatory responses, and sympathetic surges. By reducing these insults, we preserve ventricular function and reduce the risk of progressive heart failure or subsequent malignant arrhythmias, thus improving overall survival.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

Critique the use of 'time to first inappropriate therapy' as the primary endpoint in MADIT-RIT. What are the potential statistical challenges when comparing device-based interventions where the treatment itself defines the detection of the endpoint?

Key Response

The endpoint is inherently linked to the device's programmed detection threshold. In a 'high-rate' arm, many SVTs that would have triggered a shock in the 'conventional' arm simply go undetected/unrecorded as therapy events. This creates a built-in advantage for the experimental arm. However, the trial robustly addressed this by including 'all-cause mortality' and 'syncope' as secondary/safety endpoints to ensure that lack of therapy did not lead to worse clinical outcomes.

Journal Editor

As a reviewer, how would you address the potential for ascertainment bias in the MADIT-RIT trial, considering it was an open-label study involving multiple device manufacturers?

Key Response

The potential for bias in an open-label trial is significant; however, MADIT-RIT mitigated this by using an independent, blinded Core Laboratory for the adjudication of all arrhythmia episodes and therapies. Since the primary endpoint relied on objective electrogram (EGM) data interpreted by experts who were unaware of the patient's assigned group, the risk of subjective bias in outcome classification was minimized.

Guideline Committee

Based on the MADIT-RIT and subsequent PROVE-IT data, what is the current strength of recommendation for high-rate/delayed-duration ICD programming, and why do these recommendations differ for secondary prevention patients?

Key Response

Current guidelines (e.g., 2017 AHA/ACC/HRS) provide a Class I recommendation for high-rate/delayed ICD programming in primary prevention patients to reduce inappropriate shocks and mortality. However, these settings are not standard for secondary prevention because those patients have demonstrated a risk for sustained, potentially fatal VT at lower rates; for them, the risk of syncope or sudden death during a 60-second delay outweighs the benefit of avoiding a shock.

Clinical Landscape

Noteworthy Related Trials

2002

MADIT-II

n = 1,232 · NEJM

Tested

Prophylactic implantable cardioverter-defibrillator

Population

Patients with prior MI and LVEF 30% or less

Comparator

Conventional medical therapy

Endpoint

All-cause mortality

Key result: Prophylactic ICD implantation resulted in a 31% reduction in the risk of death compared to conventional medical therapy.

2005

SCD-HeFT

n = 2,521 · NEJM

Tested

Implantable cardioverter-defibrillator vs. amiodarone

Population

Patients with NYHA class II or III heart failure and LVEF 35% or less

Comparator

Placebo

Endpoint

All-cause mortality

Key result: ICD therapy significantly reduced the risk of death by 23% in patients with heart failure, whereas amiodarone did not provide a survival benefit.

2013

ADVANCE III

n = 1,902 · Circulation

Tested

Long detection interval (30 out of 40 intervals) for ICD shocks

Population

Patients with an indication for an ICD or CRT-D

Comparator

Standard detection interval (18 out of 24 intervals)

Endpoint

Number of inappropriate shocks

Key result: Programming long detection intervals significantly reduced the number of inappropriate ICD shocks and anti-tachycardia pacing compared to standard intervals.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis